← Back to Calendar

bezuclastinib

Cogent Biosciences · $COGT
Standard Review Phase 2 Breakthrough Therapy Orphan Drug
Catalyst Date
June 15, 2026
Time Remaining
63 days
Review Type
Standard (10 mo)

Live Company Data NMS

Updated 3m ago · Data: FMP
Current Price
$36.37 +804.73%
+$32.35 today
Day: $35.82 – $37.58
Market Cap
N/A
Shares out: 162.31M
Float: 150.97M
52-Week Range
$4.12
$43.73
Current price is at 81% of 52-week range
Avg Volume
2.15M
Beta
0.47
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $COGT catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Advanced systemic mastocytosis (AdvSM)

Key Notes

APEX trial Phase 2 data. Bezuclastinib is a highly selective KIT D816V inhibitor for systemic mastocytosis. Expected presentation at a major oncology conference mid-2026. NDA filing planned following data.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar